title: A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.
abstract: There is a need to identify the regulatory gene interaction of anticancer drugs on target cancer cells. Whole genome expression profiling offers promise in this regard, but can be complicated by the challenge of identifying the genes affected by hundreds to thousands of genes that induce changes in expression. A proteasome inhibitor, bortezomib, could be a potential therapeutic agent in treating adult T-cell leukemia (ATL) patients, however, the underlying mechanism by which bortezomib induces cell death in ATL cells via gene regulatory network has not been fully elucidated. Here we show that a Bayesian statistical framework by VoyaGene(®) identified a secreted protein acidic and rich in cysteine (SPARC) gene, a tumor-invasiveness related gene, as a possible modulator of bortezomib-induced cell death in ATL cells. Functional analysis using RNAi experiments revealed that inhibition of the expression SPARC by siRNA enhanced the apoptotic effect of bortezomib on ATL cells in accordance with an increase of cleaved caspase 3. Targeting SPARC may help to treat ATL patients in combination with bortezomib. This work shows that a network biology approach can be used advantageously to identify the genetic interaction related to anticancer effects.
authors.affiliation: Intractable Immune System Disease Research Center, Tokyo Medical University, Tokyo, Japan.
authors.forename: Junko H
authors.initials: JH
authors.lastname: Ohyashiki
authors.forename: Ryoko
authors.initials: R
authors.lastname: Hamamura
authors.forename: Chiaki
authors.initials: C
authors.lastname: Kobayashi
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki